Retatrutide Delivers Unprecedented Weight Loss in Phase 3
Eli Lilly's retatrutide has shown significant weight loss results in the TRIUMPH-1 phase 3 trial. Participants lost an average of 28.3% of their body weight over 80 weeks, with some achieving a BMI below 30. Experts express cautious optimism, noting the need for further peer-reviewed data to confirm these findings.
- ▪Retatrutide is a triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors.
- ▪Participants on the 12 mg dose lost an average of 28.3% of their body weight, while 45.3% achieved ≥ 30% weight loss.
- ▪Two-thirds of participants on the highest dose achieved a BMI less than 30, indicating a move out of the obesity range.
Opening excerpt (first ~120 words) tap to expand
Retatrutide, Eli Lilly’s first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the TRIUMPH-1 phase 3 trial.Retatrutide is an investigational, triple hormone receptor agonist that activates the body's receptors for GIP, GLP-1, and glucagon. It’s given as a once-weekly injection.Meaningful Results at Three Doses Trial participants were adults with obesity or overweight and at least one weight-related health condition, but without diabetes. They were randomized to one of three retatrutide doses or placebo for 80 weeks.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
